Flat-sum system to boost Japan generic uptake
This article was originally published in Scrip
Executive Summary
Deeply embedded prescriber reservations about product quality and supply have so far hindered the growth of Japan's generics sector, but the wider adoption of diagnosis procedure combination (DPC) reimbursement and changes to prescription forms will drive steady market expansion, one expert predicts.